Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg.
Phase of Trial: Phase III
Latest Information Update: 15 May 2014
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 25 Mar 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 22 Mar 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 16 May 2012 Planned patient number is 100 as reported by ClinicalTrials.gov.